Drug Profile
MK 8666
Alternative Names: MK-8666Latest Information Update: 22 Mar 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action FFAR1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 19 Mar 2014 Merck completes a phase I clinical trial in Type-2 diabetes mellitus in USA (NCT01971554)
- 04 Nov 2013 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)